Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non-Current Liabilities: 2012-2018

Historic Other Non-Current Liabilities for Fennec Pharmaceuticals (FENC) over the last 3 years, with Jun 2018 value amounting to $167,000.

  • Fennec Pharmaceuticals' Other Non-Current Liabilities rose 206.37% to $167,000 in Q2 2018 from the same period last year, while for Jun 2018 it was $167,000, marking a year-over-year increase of 206.37%. This contributed to the annual value of $167,000 for FY2017, which is 406.06% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Other Non-Current Liabilities of $167,000 as of Q2 2018, which was down 0.00% from $167,000 recorded in Q4 2017.
  • Fennec Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $5.5 million for Q1 2014, and its period low was -$157,000 during Q2 2017.
  • Over the past 3 years, Fennec Pharmaceuticals' median Other Non-Current Liabilities value was $55,000 (recorded in 2016), while the average stood at $53,333.
  • In the last 5 years, Fennec Pharmaceuticals' Other Non-Current Liabilities surged by 2,342.59% in 2014 and then crashed by 97.34% in 2015.
  • Fennec Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $1.3 million in 2014, then plummeted by 93.78% to $82,000 in 2015, then crashed by 59.76% to $33,000 in 2016, then soared by 406.06% to $167,000 in 2017, then spiked by 206.37% to $167,000 in 2018.
  • Its last three reported values are $167,000 in Q2 2018, $167,000 for Q4 2017, and -$157,000 during Q2 2017.